Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04767035 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine
A Phase 1 study of Procedural Sedation, sponsored by Melt Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04767035 is a Phase 1 study of Procedural Sedation that has completed, run by Melt Pharmaceuticals. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04767035, a Phase 1 study of Procedural Sedation, has completed, sponsored by Melt Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine under Fasted Conditions in Healthy Volunteers
Conditions Studied
Interventions
- DRUG midazolam / ketamine sublingual tablet
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04767035
The ClinicalTrials.gov registry entry for NCT04767035 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melt Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Procedural Sedation appearing as the primary indexed condition, and to 1 intervention - of which midazolam / ketamine sublingual tablet is the first listed.
NCT04767035 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04767035 about?
NCT04767035 is a clinical study titled "Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine". A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine under Fasted Conditions in Healthy Volunteers
What is the current status of trial NCT04767035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-12-01. Estimated completion is 2021-01-14.
What conditions does trial NCT04767035 study?
This clinical trial studies the following conditions: Procedural Sedation.
What interventions are being tested in trial NCT04767035?
The interventions under investigation include: midazolam / ketamine sublingual tablet (DRUG).
Who is sponsoring clinical trial NCT04767035?
This trial is sponsored by Melt Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04767035 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Procedural Sedation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.